Ask AI
ProCE Banner Activity

PURPOSE 5: Persistence on Twice-Yearly SC LEN vs Daily Oral FTC/TDF for PrEP in France and the UK

Conference Coverage
Slideset

In the open-label PURPOSE 5 study, which compared injectable twice-yearly lenacapavir PrEP with daily oral FTC/TDF PrEP in people with an indication for PrEP in France and the United Kingdom, persistence on PrEP after 1 year was significantly higher in people assigned lenacapavir. Twice-yearly injectable lenacapavir was well tolerated with a safety profile consistent with previous reports. 

Released: November 12, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions